Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.

Antimicrobial agents and chemotherapy - 1 Jun 2014

Chatterji Udayan, Garcia-Rivera Jose A, Baugh James, Gawlik Katarzyna, Wong Kelly A, Zhong Weidong, Brass Clifford A, Naoumov Nikolai V, Gallay Philippe A

Abstract excerpt

Alisporivir (ALV), a cyclophilin inhibitor, is a host-targeting antiviral (HTA) with multigenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. Recent advances have supported the concept of interferon (IFN)-free regimens to treat chronic hepatitis C. As the most advanced oral HTA, ALV with direct-acting antivirals (DAAs) represents an attractive drug combination for IFN-free therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophilin A
Share to Cyclophilins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclosporine

Share to Drug Synergism

Share to Drug Therapy, Combination

Share to Hepatitis C

Share to Replicon

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24687498
DOI: 10.1128/AAC.00016-14
PMCID: PMC4068438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.PMID 24687498Read ↗

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.Semantic proximity Read ↗

Profile of alisporivir and its potential in the treatment of hepatitis C.Semantic proximity Read ↗

The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.Semantic proximity Read ↗

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.Semantic proximity Read ↗

Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor DaclatasvirSemantic proximity Read ↗

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).Semantic proximity Read ↗

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.Semantic proximity Read ↗

Interferon free therapy with direct acting antivirals for HCV.Semantic proximity Read ↗

Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.Semantic proximity Read ↗

Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.Semantic proximity Read ↗

Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.Semantic proximity Read ↗

Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.